ABBV Trading Analysis - 10/23/2026 02:03 PM — TRU-SENTIMENT

News Headlines & Context

The following items are based on general knowledge and are separated from the data-driven analysis below:

• AbbVie's ex-dividend date of October 15, 2026 passed with a $6.92 annual dividend rate (2.39% yield), a recurring income catalyst for shareholders.
• Recent pipeline updates for immunology drugs Skyrizi and Rinvoq continue to show strong prescription growth, supporting long-term revenue stability.
• Patent cliff concerns for Humira remain a known overhang, though offset by newer product ramp.
• No major earnings release is indicated immediately ahead; next fiscal year end is December 2025 per fundamentals, with typical Q3 reporting expected later in the period.
• Headlines reflect stable big-pharma narrative; options flow shows aggressive bullish conviction that is not obviously matched by overbought technicals in the embedded data.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data:

• Trailing P/E is 81.20 with trailing EPS of $3.56; valuation is elevated versus typical pharmaceutical peers, though sector compare fields (PEG, PriceToBook) are null.
• Dividend yield 2.39% with rate $6.92 and ex-date 2026-10-15; market cap $502.52B, shares out 1.77B.
• Beta 0.11 indicates very low market correlation; 52-week range $190.75 to $291.40, current price near top.
• Institutional ownership 52.91%; average volume 5.06M vs 20-day vol avg 2.83M in indicators.
• Historical volatility 18.78%; revenue growth, margins, ROE, debt/equity, FCF all null — cannot assess directly.
• Analyst target mean and recommendation key are null; no consensus context provided.
• Fundamentals show high multiple and low beta; technicals show overbought RSI 74.19 with bullish options, a divergence from conservative valuation.

Current Market Position

Current price from indicators: $284.37 (2026-10-22 close). Daily history shows 2026-10-22 open $284.57, high $285.76, low $278.01, close $284.37, volume 3,887,207. Recent action: peaked at 30-day high $291.40 on 2026-10-15, pulled to $283.44 by 2026-10-19, bounced to $287.91 on 2026-10-20, then eased to $284.37.

Minute bars (2026-10-21 to 2026-10-22 15:55): start 09:30 $287.63, drift lower to final $284.57 at 15:55 with volume spike 379,569 at last bar. Intraday momentum is softening but stable near $284.40.

Technical Analysis

• SMA alignment: 5 > 20 > 50 ($285.11 > $273.98 > $265.43) — bullish stack, no bearish cross.
• RSI 74.19 overbought; momentum stretched but not reversing.
• MACD 6.47, signal 5.18, hist 1.29 — positive, bullish bias.
• Bollinger mid $273.98, price $284.37 inside upper $292.29; no squeeze, mild expansion.
• 30-day range $253.92–$291.40; price at ~89% of range, near top.

True Sentiment Analysis (Delta 40-60 Options)

Options flow (2026-10-23 14:03) methodology delta 40-60 only:

Call Volume: $2,062,790 (93.2%) Put Volume: $149,950 (6.8%) Total: $2,212,740

• Sentiment: Bullish with 1,097 call contracts vs 90 put contracts.
• Pure directional conviction strongly favors calls; near-term expectations upward.
• Divergence: options bullish while RSI overbought and spread engine cites "no clear direction" technically.

Key Price Levels (Observational Only)